<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654455</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_1049</org_study_id>
    <nct_id>NCT04654455</nct_id>
  </id_info>
  <brief_title>Prospective Study Evaluating Dry Eye in Patients Operated on for Ametropia by LASIK Surgery and Treated With REPADROP</brief_title>
  <acronym>PREPADROP</acronym>
  <official_title>Prospective Study Evaluating Dry Eye in Patients Operated on for Ametropia by LASIK Surgery and Treated With REPADROP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LASIK is a refractive surgery technique widely used in France. Postoperatively, the classic&#xD;
      treatment after LASIK consists of instilling drops to reduce dry eyes. REPADROP® is an&#xD;
      innovative eye drops stimulating corneal innervation. To date no study has quantified the&#xD;
      improvement in dry eye syndrome and thus the quality of life of patients using REPADROP®.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in OSDI (Ocular Surface Disease Index) score</measure>
    <time_frame>3 Months</time_frame>
    <description>Variation in OSDI (Ocular Surface Disease Index) score between 1 month and 3 months post-LASIK. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability.</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ametropia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Describe the evolution of dry eye between 1 month and 3 months post-LASIK</intervention_name>
    <description>Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient admitted to hospital for LASIK surgery for ametropia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age over 18&#xD;
&#xD;
          -  Planned bilateral LASIK surgery&#xD;
&#xD;
          -  Use of Repadrop as postoperative eye drops&#xD;
&#xD;
          -  Patient agreement to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of corneal pathology&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  History of treatment with REPADROP® or CACICOL® or NGF® (other eye drops which are no&#xD;
             longer available on the market to date but which would also improve corneal healing)&#xD;
&#xD;
          -  Ongoing treatment with topical cyclosporine&#xD;
&#xD;
          -  Presence of punctal plugs&#xD;
&#xD;
          -  Adults who are the subject of a legal protection measure (guardianship, curators)&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ROMAIN MOUCHEL, MD</last_name>
    <phone>04 72 11 95 13</phone>
    <phone_ext>+33</phone_ext>
    <email>romain.mouchel@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MAXIME KERN, RESIDENT</last_name>
    <phone>04 72 11 95 13</phone>
    <phone_ext>+33</phone_ext>
    <email>maxime.kern@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROMAIN MOUCHEL, MD</last_name>
      <phone>04 72 11 95 13</phone>
      <phone_ext>+33</phone_ext>
      <email>romain.mouchel@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

